文献速递眼底病与葡萄膜炎

增殖性糖尿病视网膜病变患者在全视网膜光凝或玻璃体腔抗VEGF注射后的失访情况

Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections.
PubMed 文献 · Ophthalmology · 2018-03-29

这项回顾性队列研究纳入2012年1月1日至2016年4月20日期间接受全视网膜光凝或玻璃体腔抗血管内皮生长因子(VEGF)注射的2302例增殖性糖尿病视网膜病变患者,约4年观察期内失访率为25.4%。全视网膜光凝组失访率28.0%高于抗VEGF注射组22.1%(P=0.001),年龄、种族和地区平均调整后总收入是失访的独立危险因素。

要点

  • 约4年观察期内,2302例增殖性糖尿病视网膜病变患者中25.4%失访。
  • 全视网膜光凝组失访率28.0%高于抗VEGF注射组22.1%(P=0.001)。
  • 年龄、种族和地区平均调整后总收入是失访的独立危险因素。

核心结论

  • 大部分增殖性糖尿病视网膜病变患者在接受全视网膜光凝或抗VEGF注射后约4年内失访。
  • 失访的关键危险因素包括年龄、种族和地区平均调整后总收入。

研究设计与样本

  • 回顾性队列研究,纳入2012年1月1日至2016年4月20日期间接受玻璃体腔抗VEGF注射或全视网膜光凝的2302例增殖性糖尿病视网膜病变患者。
  • 测量每次操作与后续随访访视之间的间隔,失访定义为至少1个间隔超过12个月。

主要发现

  • 约4年观察期内,1718例(74.6%)患者在操作后进行了随访,584例(25.4%)失访。
  • 全视网膜光凝组失访率28.0%,抗VEGF注射组22.1%(P=0.001)。
  • 失访率随年龄增加而降低:≤55岁组28.1%,56至65岁组27.0%,>65岁组20.9%(P=0.002)。
  • 失访率因种族而异:白人19.4%,非洲裔美国人30.2%,亚洲人19.7%,西班牙裔、美洲原住民和太平洋岛民38.0%,未报告种族者34.9%(P<0.001)。
  • 失访率随地区平均调整后总收入降低而升高:≤40000美元组33.9%,41000至80000美元组24.0%,>80000美元组19.7%(P<0.001)。

关键数值与推荐

  • 失访定义为至少1个操作与后续随访访视间隔超过12个月。
  • 多因素回归中,操作类型、年龄、种族和地区平均调整后总收入均为失访的显著独立危险因素(P<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Loss to follow-up (LTFU) may contribute to vision loss in patients with active proliferative diabetic retinopathy (PDR). The aim of this study is to determine and compare the rates of LTFU in patients with PDR receiving panretinal photocoagulation (PRP) or intravitreal injections (IVIs) with anti-vascular endothelial growth factor (VEGF) over approximately 4 years. Moreover, this study evaluates various risk factors for LTFU. DESIGN: Retrospective cohort study. PARTICIPANTS: A total of 2302 patients with PDR receiving IVIs with anti-VEGF or PRP between January 1, 2012, and April 20, 2016. METHODS: Intervals between each procedure and the subsequent follow-up visit were measured. Loss to follow-up was defined as at least 1 interval exceeding 12 months duration. MAIN OUTCOME MEASURES: The LTFU rates and associated risk factors. RESULTS: A total of 1718 patients (74.6%) followed up postprocedure and 584 patients (25.4%) were LTFU over approximately 4 years. Of the patients receiving PRP, 28.0% were LTFU compared with 22.1% of patients receiving IVI with anti-VEGF (P = 0.001). The LTFU rates decreased as age increased, with rates of 28.1% for patients aged ≤55 years, 27.0% for patients aged 56 to 65 years, and 20.9% for patients aged >65 years (P = 0.002). Loss to follow-up also differed by race, with rates of 19.4% for whites, 30.2% for African Americans, 19.7% for Asians, 38.0% for Hispanics, Native Americans, and Pacific Islanders, and 34.9% for patients of unreported race (P < 0.001). The LTFU rates also increased as regional average adjusted gross incomes (AGIs) decreased, with rates of 33.9% for patients with regional average AGI of ≤$40 000, 24.0% for patients with regional average AGI from $41 000 to $80 000, and 19.7% for patients with regional average AGI >$80 000 (P < 0.001). Procedure type, age, race, and regional average AGI were all significant (P < 0.05) independent risk factors of LTFU in the multivariate regression. CONCLUSIONS: A large proportion of patients with PDR were LTFU after receiving PRP or an anti-VEGF injection over approximately 4 years. Key risk factors included age, race, and regional average AGI.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Obeid A, Gao X, Ali FS, et al. Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections. Ophthalmology. 2018. PMID: 29606377. doi:10.1016/j.ophtha.2018.02.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。